New Insights into the Binding Mechanism of Co-regulator BUD31 to AR AF2 Site: Structural Determination and Analysis of the Mutation Effect

(E-pub Ahead of Print)

Author(s): Tianqing Song, Jiazhong Li*.

Journal Name: Current Computer-Aided Drug Design

Become EABM
Become Reviewer


Introduction: Androgen receptor (AR) plays a pivotal role in the development of male sex and contributes to prostate cancer growth. Different from other nuclear receptors that bind to the co-regulator LxxLL motif in coregulator peptide interaction, the AR Ligand Binding Domain (LBD) prefers to bind to the FxxLF motif. BUD31, a novel co-regulator with FxxLF motif, has been demonstrated to suppress wild-type and mutated AR-mediated prostate cancer growth.

Methods: To find out the interaction mechanisms of BUD31 with WT/T877A/W741L AR complex, molecular dynamics simulations were employed to study the complex BUD31 and WT/mutant ARs. The molecular mechanics Poisson-Boltzmann surface area (MM-PBSA) results demonstrated that T877A and W741L point mutations can reduce the binding affinity between BUD31 and AR. The RMSF and dynamic cross-correlation analysis indicated that amino acid point mutations can affect the motions of loop residues in the AR structure.

Results: These results indicated that AR co-regulator binding site AF2 can serve as a target for drug discovery to solve the resistance problem.

Keywords: BUD31; Androgen receptor; AF2 binding site; Interaction mechanism; Molecular dynamics

Rights & PermissionsPrintExport Cite as

Article Details

(E-pub Ahead of Print)
DOI: 10.2174/1573409915666190502153307
Price: $95

Article Metrics

PDF: 1